Study details
Enrolling now
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease
Bernard (Barry) Baumel
NCT IDNCT06781333ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
8
Study length
about 1.1 years
Ages
55–90
Locations
1 site in FL
About this study
Researchers are testing if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease. The trial will last for 412 days and involve approximately 8 adults.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive hMSC
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Neurology